Company Valuation: Seres Therapeutics, Inc.

Data adjusted to current consolidation scope
Fiscal Period: December 2021 2022 2023 2024 2025 2026 2027 2028
Market Cap 1 765.1 697.7 181 141.9 134.6 33.3 - -
Change - -8.81% -74.06% -21.59% -5.12% -75.26% - -
Enterprise Value (EV) 634.3 697.3 266.9 202.7 134.6 33.3 33.3 33.3
Change - 9.93% -61.72% -24.05% -33.6% -75.26% 0% 0%
P/E -11.6x -2.42x -1.57x - 23.3x -0.95x -0.68x -0.67x
PBR - - -4.21x 10.4x - - - -
PEG - -0x 0x - - 0x -0x -1.1x
Capitalization / Revenue 5.28x 97.9x 1.43x - 171x 2.41x 122x 122x
EV / Revenue 0x 0x 0x - 0x 2.41x 122x 122x
EV / EBITDA -0x -0x -0x -0x - -0.45x -0.43x -0.39x
EV / EBIT -0x -0x -0x -0x -0x -0.5x -0.42x -0.38x
EV / FCF - - - - - - - -
FCF Yield - - - - - - - -
Dividend per Share 2 - - - - - - - -
Rate of return - - - - - - - -
EPS 2 -14.4 -46.2 -17.8 - 0.64 -3.515 -4.945 -4.975
Distribution rate - - - - - - - -
Net sales 1 144.9 7.128 126.3 - 0.789 13.8 0.2735 0.2735
EBITDA 1 -58.55 -239.9 -96.14 -115.8 - -74.6 -77.3 -85
EBIT 1 -64.49 -246.5 -102.4 -121.3 -93.97 -66.09 -79.44 -88.13
Net income 1 -65.58 -250.2 -113.7 0.136 5.696 -37.49 -78.95 -87.69
Net Debt -130.8 -0.44 85.97 60.85 - - - -
Reference price 2 166.600 112.000 28.000 16.620 14.880 3.350 3.350 3.350
Nbr of stocks (in thousands) 4,592 6,230 6,463 8,537 9,047 9,941 - -
Announcement Date 01/03/22 07/03/23 05/03/24 13/03/25 12/03/26 - - -
1USD in Million2USD
Estimates

P/E, Detailed evolution



P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
-0.95x - - - 33.3M
21.73x7.77x15.61x1.37% 74.46B
31.25x9.01x28.06x0.04% 60.14B
33.64x6.03x18.07x0.97% 48.15B
34.63x3.34x14.4x-.--% 44.25B
-21.16x229.18x-22.81x-.--% 43.99B
47.94x5.54x30.43x-.--% 41.61B
26.89x7.76x19.96x0.42% 29.97B
33.91x7.26x18.84x-.--% 29.31B
-70.02x13.44x-68.51x-.--% 24.93B
Average 13.79x 32.15x 6.01x 0.31% 39.68B
Weighted average by Cap. 19.57x 31.88x 10.24x 0.41%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA


  1. Stock Market
  2. Stocks
  3. MCRB Stock
  4. Valuation Seres Therapeutics, Inc.